American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activating mTOR mutations are detrimental in nutrient-poor conditions
    Journal Article

    Bielska, A. A.; Harrigan, C. F.; Kyung, Y. J.; Morris, Q.; Palm, W.; Thompson, C. B.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Predictive biomarkers of overall survival in patients with metastatic renal cell carcinoma treated with IFNα ± bevacizumab: Results from CALGB 90206 (alliance)
    Journal Article

    Nixon, A. B.; Halabi, S.; Liu, Y.; Starr, M. D.; Brady, J. C.; Shterev, I.; Luo, B.; Hurwitz, H. I.; Febbo, P. G.; Rini, B. I.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer
    Journal Article

    Schoenfeld, A. J.; Rizvi, H. A.; Memon, D.; Shaverdian, N.; Bott, M. J.; Sauter, J. L.; Tsai, C. J.; Lihm, J.; Hoyos, D.; Plodkowski, A. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors
    Journal Article

    Kim, T. W.; Burris, H. A. 3rd; de Miguel Luken, M. J.; Pishvaian, M. J.; Bang, Y. J.; Gordon, M.; Awada, A.; Camidge, D. R.; Hodi, F. S.; McArthur, G. A.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human phase I/II ICONIC trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-High CD4 T-cell populations and predictors of response
    Journal Article

    Yap, T. A.; Gainor, J. F.; Callahan, M. K.; Falchook, G. S.; Pachynski, R. K.; LoRusso, P.; Kummar, S.; Gibney, G. T.; Burris, H. A.; Tykodi, S. S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Phase Ib/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma
    Journal Article

    Schuler, M.; Zimmer, L.; Kim, K. B.; Sosman, J. A.; Ascierto, P. A.; Postow, M. A.; De Vos, F. Y. F. L.; van Herpen, C. M. L.; Carlino, M. S.; Johnson, D. B.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer
    Journal Article

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Nguyen, B.; Stopsack, K. H.; Kreitzer, C.; Rajanala, S. H.; Ghale, R.; Mazzu, Y. Z.; Pillarsetty, N. V. K.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial
    Journal Article

    Lee, C. H.; Motzer, R.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U.; Liu, S.; McCune, S.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Orthovoltage X-rays exhibit increased efficacy compared with γ-rays in preclinical irradiation
    Journal Article

    Bell, B. I.; Vercellino, J.; Brodin, N. P.; Velten, C.; Nanduri, L. S. Y.; Nagesh, P. K. B.; Tanaka, K. E.; Fang, Y.; Wang, Y.; MacEdo, R.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types
    Journal Article

    Sinha, N.; Sinha, S.; Valero, C.; Schäffer, A. A.; Aldape, K.; Litch, K.; Chan, T. A.; Morris, L. G. T.; Ruppin, E.
    Cancer Research (2022)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: